Controlled CRISPR‐Cas9 Ribonucleoprotein Delivery for Sensitized Photothermal Therapy

Manipulation of CRISPR delivery for stimuli‐responsive gene editing is crucial for cancer therapeutics through maximizing efficacy and minimizing side‐effects. However, realizing controlled gene editing for synergistic combination therapy remains a key challenge. Here, a near‐infrared (NIR) light‐triggered thermo‐responsive copper sulfide (CuS) multifunctional nanotherapeutic platform is constructed to achieve controlled release of CRISPR‐Cas9 ribonucleoprotein (RNP) and doxorubicin for tumor synergistic combination therapy involving in gene therapy, mild‐photothermal therapy (PTT), and chemotherapy. The semiconductor CuS serves as a “photothermal converter” and can stably convert NIR light (808 nm) into local thermal effect to provide photothermal stimulation. The double‐strand formed between CuS nanoparticle‐linked DNA fragments and single‐guide RNA is employed as a controlled element in response to photothermal stimulation for controlled gene editing and drug release. Hsp90α, one subunit of heat shock protein 90 (Hsp90), is targeted by Cas9 RNP to reduce tumor heat tolerance for enhanced mild‐PTT effects (≈43 °C). Significant synergistic therapy efficacy can be observed by twice NIR light irradiation both in vitro and in vivo, compared to PTT alone. Overall, this exogenously controlled method provides a versatile strategy for controlled gene editing and drug release with potentially synergistic combination therapy. A novel thermo‐responsive nanotherapeutic platform named CuS‐RNP/DOX@PEI is established, which is triggered by 808 nm near‐infrared light irradiation. This exogenously controlled method can be used in combination tumor therapy, including gene‐therapy, mild‐photothermal therapy, and chemotherapy, which provides a versatile strategy for controlled gene editing and drug release for synergistic therapy with maximizing efficacy and minimizing side‐effects.